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ABSTRACT
Objectives Transcatheter aortic valve implantation 
(TAVI) is performed in elderly patients with severe aortic 
valve stenosis and increased operative risks. We tested 
the hypothesis that acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE) have a predictive value 
for prevalent complications after TAVI and could serve 
as indicators of systemic inflammation in the early 
postoperative period.
Design Prospective observational study.
Setting This study is a secondary analysis of multicentre 
CESARO- study.
Participants 48 patients with TAVI were included and 43 
obtained the complete assessment.
Primary and secondary outcome measures Patients’ 
clinical parameters, demographic data, peripheral AChE 
and BChE activities and routine blood markers were 
assessed throughout the perioperative period using 
bedside point- of- care measurements for AChE and BChE. 
Postoperative complication screening was conducted up 
to the third postoperative day and included infections, 
delirium and heart- rhythm disturbances. After assessment, 
the patients were divided into complication and 
noncomplication group.
Results Of 43 patients, 24 developed postsurgical 
complications (55.8%). Preoperative assessment showed 
no significant differences regarding demographic data and 
laboratory markers, but preoperative BChE levels were 
significantly lower in patients who developed postoperative 
complications (complication group 2589.2±556.4 vs 
noncomplication group 3295.7±628.0, Cohen’s r=0.514, 
p<0.001). In complication group, we observed an early, 
sustained reduction in BChE activity from preoperative to 
postoperative period. In complication group, BChE levels 
were significantly lower at each time point compared 
with noncomplication group. AChE activity showed no 
significant difference between both groups. Complication 
group also had longer stay in hospital overall.
Conclusion BChE could be a useful perioperative 
biomarker to identify patients with a higher risk for 
postoperative complications after TAVI. By using point- of- 
care measurements, the levels of BChE are fast available 
and can lead to an early targeted therapy. Predicting the 
length of the hospital stay might play an important role in 
staff and resource management for these patients.
Trial registration number NCT01964274; Post- results.
INTRODUCTION
Recently, transcatheter aortic valve implan-
tation (TAVI) has become the therapeutic 
standard for medical treatment in elderly, 
multimorbid patients with severe aortic valve 
stenosis and increased operative risks.1 2 TAVI 
involves the implantation of a prosthetic valve, 
which is introduced with a catheter through 
transfemoral (TF), transapical (TA) or direct 
transaortic access. Usually, the TF approach is 
preferred because thoracotomy and penetra-
tion of the myocardium are not needed. The 
TA approach is common, if severe atheroscle-
rotic disease does not allow retrograde inser-
tion of the catheter. In patients with severe 
aortic stenosis, who could not undergo a 
surgical replacement of the aortic valve, TAVI 
significantly reduced the rates of death at 
any cause, compared with standard therapy.3 
However, previous studies have shown that 
pneumonia, acute renal failure, indication 
for a permanent pacemaker and delirium 
were the most frequently recorded compli-
cations after TAVI.4 Covello et al5 reported a 
pneumonia rate of 7%–8% after TAVI. The 
Strengths and limitations of this study
 ► This study is a secondary analysis of the prospective 
observational multicentre CESARO study.
 ► Our study included 48 cardiosurgical patients with 
an observation time of 3 days.
 ► Butyrylcholinesterase could be a useful periopera-
tive biomarker to identify patients with a higher risk 
for postoperative complications after transcatheter 
aortic valve implantation.
 ► By using point- of- care measurements, the levels of 
BChE are fast available and can lead to an early tar-
geted therapy.
 ► Predicting the length of the hospital stay might play 
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incidence of delirium after TAVI is reported as 29% in 
the literature.6
Acetylcholinesterase (AChE) and butyrylcholinesterase 
(BChE) are the focus of current research. Recent studies 
have shown that AChE and BChE serve as diagnostic 
markers of low- grade systemic inflammation.7–9 Rapid 
changes in cholinesterase activity have also been reported 
in patients after acute trauma, infections, burns and crit-
ical illness.10–14 Both enzymes may serve as indicators of 
systemic inflammation and may have a predictive value for 
mortality in critically ill patients. Zivkovic et al13 showed 
that reduced serum activity of BChE indicates severe 
systemic inflammation in critically ill patients. Further-
more, a recent study showed that a sustained reduction 
in serum cholinesterase enzyme activity predicts patient 
outcome following sepsis.15
Other studies postulate low preoperative plasma cholin-
esterase activity as a risk marker of postoperative delirium 
in elderly patients.16 A recently published study on 
cholinesterase activity in cardiac surgical patients showed 
no postoperative differences in cholinesterase activities 
between delirious and nondelirious patients but showed 
a perioperative decrease in BChE, which was potentially 
caused by cardiopulmonary bypass.17 However, due to 
high variability in the aetiology and progress of clinical 
conditions, it was difficult to determine whether the 
changes in the enzyme activity correlated with the emer-
gence of disease or were affected by concomitant factors 
such as cardiopulmonary bypass.
This is the first study to investigate the roles of AChE 
and BChE as inflammatory markers in cardiac surgical 
patients under standardised perioperative conditions 
without using cardiopulmonary bypass. Our aim of the 
present study is to evaluate if there is a predictive associ-
ation of perioperative determination of AChE and BChE 
activity and the occurrence of postoperative complica-
tions after TAVI.
MATERIALS AND METHODS
Ethics approval statement and patient population
This work is a secondary analysis of the prospective obser-
vational multicentre CESARO study, powered for the 
detection of postoperative delirium. The CESARO study 
was initiated at Charité—Universitätsmedizin Berlin, 
Department of Anesthesiology and Operative Intensive 
Care Medicine.
Inclusions criteria: minimum age of 18 years, admission 
to intensive care unit (ICU) following elective TAVI in 
general anaesthesia.
Exclusion criteria: missing consent, patients with a 
known pseudocholinesterase deficiency, patients with 
language, visual or hearing impairments.
Data
Data were acquired from anaesthetic charts (Medlinq 
V.1.3, Hamburg, Germany), the patient document system 
used in the ICU (Metavision, iMDsoft, Tel Aviv, Israel) 
and medical reports from the electronic hospital infor-
mation system (SAP, Walldorf, Germany) from the preop-
erative, intraoperative and postoperative periods until the 
patients were discharged from the hospital.
Preoperative variables
Preoperative data included demographic data, such as 
age, sex, height, weight, regular use of alcohol and nico-
tine, American Society of Anesthesiologists (ASA) class, 
logistic European System for Cardiac Operative Risk 
Evaluation (EuroSCORE), New York Heart Association 
class and left ventricular ejection fraction. The patients’ 
previous medical history was examined for conditions 
such as chronic kidney disease, cerebrovascular events, 
including stroke and transient ischaemic attacks, myocar-
dial infarction, chronic obstructive pulmonary disease, 
diabetes mellitus and pre- existing cardiac arrhythmias. 
Furthermore, we evaluated the preoperative anticho-
linergic burden using the anticholinergic drug scale.18 
This scale ranges from 0 (no anticholinergic activity) 
to 3 (highest anticholinergic activity). Each long- term 
drug was screened for its anticholinergic activity, and for 
each patient, the number of points was assessed. Every 
patient was screened for preoperative delirium, using the 
nursing delirium screening scale (NU- DESC). Preopera-
tive assessment of AChE, BChE, C reactive protein (CRP), 
leucocytes, haemoglobin and creatinine was performed 
(table 1).
Intraoperative variables
Key elements of intraoperative data included the selected 
access type, anaesthetic procedure, transfusion of eryth-
rocyte concentrates and extubation rate as well as the 
procedure duration.
Postoperative variables
Postoperative data included the patient’s stay in the ICU 
and the stay in hospital in general. Next to the sampling 
of laboratory markers, every patient was screened for 
delirium with NU- DESC for the first 3 days after surgery. 
Patients were daily assessed for pain, using the numeric 
rating scale (NRS score: 0=no pain—10=maximum pain). 
Furthermore, any complication in recovery time was 
noticed. Mortality reasons are divided into cardiac, acute 
kidney injury, cardiovascular events and infections.
Variables
Delirium
Delirium screening was conducted perioperatively using a 
validated screening tool (NU- DESC).19 NU- DESC assesses 
five dimensions: orientation, behaviour, communication, 
illusion/hallucination and psychomotor retardation. The 
symptoms are rated on a three- point scale, whereas a 
score of 2 or more cumulative points indicated delirium. 
Delirium assessment was performed 1 day prior to the 
operation, on admission to ICU and daily up to the third 
postoperative day. Patients with Richmond Agitation 
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Laboratory parameters
Blood samples were taken from every patient at following 
time points: 1 day before operation (screening), shortly 
before anaesthetic induction, on admission to ICU, 1 day 
after surgery and 2 days after surgery (figure 1). The 
measurements included the determination of AChE and 
BChE. Both were measured in 10 µl whole blood, using 
ChE check mobile, a validated point- of- care testing device 
(ChE check mobile, Securetec Detektions- Systeme AG, 
Neubiberg, Germany; In- Vitro- Diagnostics Guideline 
98/79/EG; DIN EN ISO 18 113–2 and −3) by following 
the manufacturer’s instructions. Also, blood count, CRP, 
creatinine were measured at each time point. Creatine 
kinase (CK) and heart enzymes (CK-MB) were measured 
on the first postoperative day in the normal laboratory 
control. Brain natriuretic Peptide (NT- proBNP) was 
measured at the screening day. To deal with missing 
values, we included three defined measurements (time 
points) into the analysis.
Postoperative complications
Since delirium, pneumonia, heart rhythm disturbances 
and acute renal failure are the most frequently reported 
complications after TAVI,4 we have screened all patients 
until the discharge of the hospital. Infection was defined 
as an increase in CRP, fever and diagnosed infection- focus 
(pneumonia, urinary tract infection, other infections). 
Delirium was diagnosed by using NU- DESC. Postoper-
ative heart rhythm disturbances were occurred by AV 
block and atrial fibrillation. Patients were divided into 
two groups: those who did not develop any postoperative 
complications (noncomplication group) and patients 
who showed one of these complications within 3 days 
after TAVI (complication group).
Operation procedure
All patients were admitted and evaluated at least 1 day 
before the operation. TAVIs were performed by the 
cardiac team (cardiac surgeon, cardiologist and cardiac 
anaesthetist) in a hybrid operating theatre, according 
to the German guidelines for TAVI procedures. All 
procedures were performed with the patients placed 
under general anaesthesia. In all patients, monitoring 
consisted of pulsoximetry, five- channel ECG, inva-
sive blood pressure, central venous pressure, urinary 
output and bladder temperature. The maintenance of 
normothermia was accomplished by a heating blanket 
placed beneath the patient. The patients received right 
ventricular pacemakers for rapid ventricular pacing 
during balloon aortic valvuloplasty and valve expansion. 
Preoxygenation was performed with pure oxygen using 
a facemask. Anaesthesia was induced with etomidate 
(Etomidat- Lipuro, B. Braun Melsungen AG, Melsungen, 
Table 1 Description of baseline data; all data are presented 
as n (number) and (%)
Characteristic Total sample (n=43)
Age (years) (M (SD)) 79.47 (5.7)
Sex (n (%))
  Male 22 (51.2)
  Female 21 (48.8)
  BMI (M (SD)) 27.93 (5.4)
ASA–PS (n (%))
  3 32 (74.4)
  4 11 (25.6)
Operative procedure (n (%))
  Transapicale TAVI 11 (25.6)
  Transfemorale TAVI 32 (74.4)
Relevant comorbidities (n (%))
  Hypertension 37 (86)
  Diabetes 16 (37.2)
  Congestive heart failure 36 (83.7)
  Congestive kidney failure 20 (46.5)
  Coronary heart disease 31 (72.1)
  Cardiac arrhythmias 25 (58.1)
  Stroke 8 (18.6)
  Nicotine 19 (44.2)
  Alcohol 8 (18.6)
  Hypothyreosis 10 (23.3)
  Hypercholesterinemia 14 (32.6)
EuroSCORE (n (%))
  Low 15 (34.9)
  Middle 18 (41.9)
  High 10 (23.3)
  Pre- operative anticholinergic drugs 16 (37.2)
ASA, American Society of Anaesthesiologists Classification; BMI, 
body mass index; TAVI, transcatheter aortic valve implantation.
Figure 1 Timeline of measurements of BChE and AChE: blood samples were taken 1 day preoperative (D O), shortly before 
anaesthetic induction (D 1), on admission to ICU (POD 0), 1 day after surgery (POD 1) and 2 days after surgery (POD 2). If the 
measuremnets could not be conducted immediatley, the samples have been cooled in a refrigerator and the measurement 


















pen: first published as 10.1136/bm




4 Michels B, et al. BMJ Open 2021;11:e042857. doi:10.1136/bmjopen-2020-042857
Open access 
Germany), remifentanil (Ultiva, GlaxoSmithKline GmbH 
KG, Munich, Germany) and rocuronium (Rocuronium 
Inresa, Inresa Arzneimittel GmbH, Freiburg, Germany) 
and maintained with sevoflurane (Sevorane, AbbVie 
Deutschland GmbH KG, Wiesbaden, Germany). Pirit-
ramide and metamizole were used as additional pain 
medication. PONV (postoperative nausea and vomiting) 
prophylaxis was used intraoperatively, depending on the 
patient’s risk. Cardiovascular drugs (eg, norepineph-
rine and dobutamine) were administered, as needed. A 
prophylactic antibiotics (1.5 g, Cefuroxim Hikma, Hikma 
Pharma GmbH, Gräfelfing, Germany) was administered 
to each patient. In the operating theatre, the patient 
was connected to a defibrillator, and a TEE (transesoph-
ageal echocardiography) probe was introduced. After 
preparing the access points and anticoagulation with 
heparin (Ratiopharm GmbH, Ulm, Germany; mean given 
dose 5293±2643 IU), the native valve was opened under 
rapid ventricular pacing, and the prothesis was implanted. 
The position and function of the prothesis were veri-
fied with TEE. Extubation of the patient was the goal at 
the end of each procedure. After surgery, patients were 
monitored for at least 12 hours in the ICU. Following this 
period, patient care continued either in the ICU or in the 
general ward. There was no use of heart–lung machines.
Patient and public involvement
Patients were not involved in the study.
Statistics
The data were electronically gathered and stored by using 
Excel (Excel 2013, Microsoft Corporation, Redmond, 
Washington). Data analysis was performed by using 
SPSS (V22.0; SPSS, Chicago, Illinois). Frequency distri-
butions and percentage rates were used for the categor-
ical variables. Data are presented as mean with SD and 
with Cohen’s r effect size. Shapiro- Wilk test was used to 
verify Gaussian distribution of the study groups. Statistical 
significance between the patient groups was tested using 
t- test, Mann- Whitney U test, analysis of variance and chi- 
quadrat. Bonferroni correction was done in case of repeat 
measurements to rule out alpha error accumulation. 
Friedman analysis of ranks was performed to compare the 
cholinesterase activity change over time in each group. A 
multivariate logistic regression analysis was performed to 
investigate the association between cholinesterase activity 




A total of 48 patients were included, and 43 patients 
completed the assessment battery. The mean age was 
79.5±5.71 years and the mean body mass index was 
27.93±5.36. There were almost equally men and women 
(22 (51.2 %) vs 21 (48.8 %), table 1). All patients received 
elective TAVI in general anaesthesia. TF access was 
selected for 32 (74 %), with TA chosen for 11 (26 %) 
patients. There was no use of heart–lung machines. The 
demographic data and pre- existing conditions are shown 
in table 1. Thirty- two (74.4 %) had an ASA- class of three, 
11 (25.6 %) of four. Except of four, every patient was extu-
bated immediately after operation and brought to ICU. 
One high- risk patient was still intubated when brought 
to ICU and died 2 days after operation by multiorgan 
failure. Another patient was extubated on the first postop-
erative day. Two patients were extubated a few hours after 
brought to ICU. Patients were discharged to a normal 
ward after 1 day and left the hospital after 13.28±6.2 days.
Postoperative complications
Twenty- four patients (55.8 %) had postoperative compli-
cations as defined above. One multimorbid and high- risk 
patient died due to multiorgan failure at ICU 2 days after 
surgery.
Of 43 patients, 12 developed postoperative delirium 
(27.9 %). Most patients developed their delirium on the 
first day after surgery.
Of 43 patients, 2 developed pneumonia. However, 
in three patients with raised infection markers and 
suspected infection, no focus was found. All of them 
received antibiotics.
There were seven patients with postoperative indication 
for pacemaker (16.3%). Overall, 12 patients developed 
heart rhythm disturbances (27.9%). Some of the patients 
developed more than one complication, for example, 
delirium or infection.
Comparison between complication and noncomplication 
group
Preoperative variables
Preoperative assessment showed no statistically signifi-
cant differences regarding demographic data and labo-
ratory routine markers like haemoglobin (p=0.917), 
leucocytes (p=0.383), CRP (p=0.716), NT- proBNP 
(p=0.563) and creatinine (p=0.089). Preoperative BChE 
levels were significantly lower in patients who developed 
postoperative complications (D 1 complication group 
2589.2±556.4 vs D 1 noncomplication group 3295.7±628.0 
Cohen’s r=0.514, p<0.001, table 2). Preoperative AChE 
enzyme activity in contrast did not show any statistically 
significant difference between complication and noncom-
plication groups. There was no statistically significant 
difference regarding pre- existing anticholinergic medi-
cation (p=0.153). There was also no statistically signifi-
cant difference regarding alcohol (p=0.226) or nicotine 
(p=0.807) consumption. Men or women did not show a 
significantly higher incidence of postoperative compli-
cations (p=0.095). There was no statistically significant 
difference between complication and noncomplication 
group regarding the anticholinergic burden (p=0.229).
Postoperative variables
All patients were postoperatively admitted to the ICU extu-
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Table 2 Perioperative laboratory markers; all data are presented as number (n) or as mean±SD
Variables Complication N M SD P value Cohens’ r
EuroSCORE Yes 24 21.8 15.4 0.824 0.034
no 19 22.8 13.5
Weight
(kg)
Yes 24 78.3 15.5 0.504 0.102
no 19 74.9 18.0
BMI
(kg/m2)
Yes 24 28.1 4.7 0.860 0.037
No 19 27.7 6.2
Age
(years)
Yes 24 79.9 5.3 0.556 0.086
No 19 78.9 6.3
NT- proBNP(pg/ml) Yes 24 6244.8 6773.1 0.563 0.099
No 19 4806.6 7809.4
Haemoglobin D 0(g/L) Yes 24 12.1 1.9 0.917 0.029
no 19 12.2 1.4
Haemoglobin POD 0(g/L) Yes 24 10.7 1.5 0.565 0.068
No 19 10.9 1.4
Haemoglobin POD 1(g/L) Yes 24 10.1 1.4 0.986 0.000
no 19 10.1 1.1
Haemoglobin POD 2(g/L) Yes 24 10.1 1.1 0.673 0.087
No 19 10.3 1.2
Haemoglobin POD 3(g/L) Yes 24 9.6 1.0 0.272 0.173
No 19 10.0 1.3
Creatinine D 0(mg/dl) Yes 24 1.4 0.7 0.089 0.247
No 19 1.1 0.4
Creatinine POD 1(mg/dl) Yes 24 1.2 0.4 0.347 0.124
No 19 1.1 0.4
Creatinine POD 2(mg/dl) Yes 24 1.5 0.8 0.188 0.223
No 19 1.2 0.4
Creatinine POD 3(mg/dl) Yes 24 1.5 1.0 0.240 0.244
No 19 1.1 0.4
Leucocytes
D 0(/nl)
Yes 24 7.8 2.1 0.383 0.131
No 19 7.3 1.6
Leucocytes
POD 1(/nl)
Yes 24 9.6 4.3 0.496 0.113
No 19 8.8 2.1
Leucocytes POD 2(/nl) Yes 24 9.9 2.7 0.616 0.081
No 19 9.4 3.5
Leucocytes POD 3(/nl) Yes 24 8.8 3.1 0.079 0.336
No 19 7.0 1.5
CRP
D 0(mg/l)
Yes 24 16.3 17.8 0.716 0.094
No 19 19.8 18.2
CRP
POD 1(mg/l)
Yes 24 31.8 21.1 0.177 0.236
No 19 22.0 18.9
CRP
POD 2(mg/l)
Yes 24 116.3 52.9 0.516 0.114
No 19 101.3 78.2
CRP
POD 3(mg/l)
Yes 24 115.3 68.5 0.113 0.284


















pen: first published as 10.1136/bm




6 Michels B, et al. BMJ Open 2021;11:e042857. doi:10.1136/bmjopen-2020-042857
Open access 
Two patients did not meet the extubation criteria in the 
operation room and were extubated a few hours later at 
ICU. One high- risk patient died at ICU due to multiorgan 
failure. One patient was extubated on the first postoper-
ative day.
Complication group showed an early, sustained and 
statistically significant decrease in BChE activity from the 
preoperative to the first postoperative measurement (D 0: 
2784.0±534.9 vs POD 0: 2379.6±525.1, p<0.001, figure 2). 
In contrast in patients without postoperative complica-
tions, we observed a delayed decrease in BChE activity 
from the preoperative to postoperative period (D 0: 
3072.6±652.1 vs POD 2: 2713.5±510.6, p<0.001, figure 2). 
In all time points, a significantly lower BChE activity was 
observed in patients with complications compared with 
patients without postoperative complication (figure 2).
Further analysis involving partial correlation and 
regression analysis showed that there was no influence of 
preoperative anticholinergic medication on BChE results 
(p=ns).
Both groups showed a moderate decrease in AChE 
activity after preoperative screening measurement 
(figure 3). From anaesthesia induction to the second 
postoperative measurement, we observed no significant 
changes in AChE activity over time in both groups. There 
were no significant differences in AChE activity between 
patients with and without complication in any time point 
(figure 3).
Variables Complication N M SD P value Cohens’ r
BChE
D 0(U/l)
Yes 24 2784.0 534.9 0.118 0.238
No 19 3072.6 652.1
BChE
D 1(U/l)
Yes 24 2589.2 556.4 <0.001 0.514
No 19 3295.7 628.0
BChE
POD 0(U/l)
Yes 24 2379.6 525.1 <0.001 0.469
No 19 2972.5 599.2
BChE
POD 1(U/l)
Ye 24 2300.3 561.0 <0.001 0.504
No 19 2936.1 523.1
BChE
POD 2(U/l)
Yes 24 2166.7 537.0 0.002 0.462
No 19 2713.5 510.6
AChE
D 0(U/gHb)
Yes 24 45.0 8.1 0.446 0.118
No 19 43.3 6.0
AChE
D 1(U/gHb)
Yes 24 42.0 10.0 0.263 0.172
No 19 39.2 4.7
AChE
POD 0(U/gHb)
Yes 24 42.9 10.0 0.051 0.295
No 19 37.6 6.4
AChE
POD 1(U/gHb)
Yes 24 41.5 9.2 0.196 0.198
No 19 38.4 5.2
AChE
POD 2(U/gHb)
Yes 24 41.2 8.2 0.058 0.294
No 19 36.5 6.8
CK
POD 1(U/l)
Yes 24 189.6 186.8 0.953 0.009
No 19 186.1 190.5
CK- MB
POD 1(ng/ml)
Yes 24 15.5 18.2 0.946 0.012
No 19 15.9 14.3
CK Index
POD 1
Yes 24 7.2 3.6 0.314 0.174
No 19 8.5 3.8
Stay in hospital (days) Yes 24 15.2 6.3 0.033 0.325
No 19 11.1 5.5
Anticholinergic burden Yes 24 0.82 1.191 0.229 0.189
No 19 0.42 0.838
AChE, acetylcholinesterase; BChE, butyrylcholinesterase; BMI, body mass index; CK, creatine kinase; CRP, C reactive protein; MB, Muscle- 
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Further analysis showed large effect sizes for the periop-
erative measurements of BChE. In contrast, effect sizes 
for AChE were much lower, which affirms the results 
above (table 2).
Patients, who developed postoperative complications, 
had a significantly longer stay in hospital in general 
(complication group: 15.2±6.3 vs noncomplication 
group: 11.1±5.5 days, Cohen’s r=0.325, p=0.033). There 
was no statistically significant difference regarding the 
stay on ICU (complication group vs noncomplication 
group Cohen’s r=0.132, p=0.379). Patients with postop-
erative delirium showed highest NU- DESC score on the 
first postoperative day (delirium: 3.3±2.6 vs nondelirium: 
0.27±0.79). The preoperative score of NU- DESC was 
0.42±0.67 within patients who developed postoperative 
delirium. Routine laboratory markers like haemoglobin, 
leucocytes, CRP, CK, CK- MB and creatinine did not show 
any statistically significant difference (complication 
group vs noncomplication group p=ns, table 2).
Furthermore, there was no statistically significant differ-
ence in EuroSCORE regarding on complication (compli-
cation group vs noncomplication group Cohen’s r=0.034, 
p=0.824, table 1).
TA versus TF
Patients who underwent TA approach declared postop-
erative higher pain levels measured by NRS (p<0.001). 
They also showed higher CRP levels on POD 2 (88.8±44.5 
vs 161.6±70.2, Cohen’s r=0.574, p<0.001) and higher 
levels of CK (110.8±134.5 vs 398.7±139.0, Cohen’s 
r=0.728, p<0.001) and CK- MB (8.3±11.8 vs 29.8±14.7, 
Cohen’s r=0.650, p<0.001) on the first postoperative day. 
There were no further statistically significant differences 
between patients with TF and TA approach, especially 
regarding on complications or BChE and AChE enzyme 
levels.
DISCUSSION
TAVI has become the therapeutic standard for medical 
treatment in elderly patients with severe aortic valve 
stenosis and increased operative risks. The primary objec-
tive of the present investigation was to evaluate the roles 
of AChE and BChE as predictive markers for prevalent 
complications in cardiosurgical patients after TAVI.
Previous studies assumed an interaction of the immune 
and cholinergic system20 and identified AChE and BChE 
as useful biomarkers for early detection of patients with 
emerging inflammation.16 Rapid changes in cholines-
terase activity have been reported in patients after acute 
trauma, infections, delirium and critical illness.10–14 Both 
enzymes may serve as indicators of systemic inflamma-
tion and may have a predictive value for mortality in 
critically ill patients. Zivkovic et al10 showed that bedside- 
measurement of BChE activity predicts patient morbidity 
and length of ICU stay following major traumatic injury.21 
Another study with patients undergoing venoarterial 
extracorporeal membrane oxygenation therapy after 
Figure 2 Time trajectories of BChE activities in patients 
with TAVI (n=43). Pre- operative (DO), shortly before 
anaesthetic induction (D 1), on admission to ICU (POD 0), 
1 day after surgery (POD 1) and 2 days after surgery (POD 
2) measurements in patients with (dashed) and without 
(solid) complication. Data are presented as median ±SD. 
*Difference between groups; # Difference within groups. 
BChE,butyrylcholinesterase; TAVI, transcatheter aortic valve 
implantation.
Figure 3 Time trajectories of AChE activities in patients 
with TAVI (n=43). Pre- operative (DO), shortly before 
anaesthetic induction (D 1), on admission to ICU (POD 0), 
1 day after surgery (POD 1) and 2 days after surgery (POD 
2) measurements in patients with (dashed) and without 
(solid) complication. Data are presented as median ±SD. 
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cardiac surgery revealed BChE as a strong predictor of 
all- cause and cardiovascular mortality.
In our present study, patients with postoperative 
complications after TAVI had significant lower preop-
erative levels of BChE compared with the noncomplica-
tion group. Effect sizes were particularly large for BChE 
measurements in this homogeneous patient group. In 
combination with common preoperative evaluation 
procedures, BChE activity may serve as a useful predictive 
indicator to identify high- risk patients. Future studies are 
needed to clarify clinical implications.
Due to high variability in the onset, aetiology and prog-
ress of clinical conditions among patients, determining 
whether changes in the enzyme activity are correlated 
with the emergence of disease or are affected by concom-
itant factors is difficult. John et al17 tested the hypothesis 
that AChE and BChE have an impact on patients after 
cardiac surgery with postoperative delirium. They showed 
that AChE increased and BChE decreased within the first 
3 days after surgery but did not discern between patients 
with and without delirium. The authors supposed that the 
perioperative change of AChE and BChE activity might 
possibly be explained by an interaction of AChE and 
BChE and the use of a cardiopulmonary bypass. In our 
present study, we evaluated the role of AChE and BChE 
activity in cardiosurgical patients after TAVI, as a stan-
dardised operative procedure without cardiopulmonary 
bypass. We could show that complication group showed 
a significantly perioperative decrease in BChE within the 
first 3 days after TAVI, despite the fact that there was no 
use of heart–lung machines in our patients. Furthermore, 
there was no use of blood products in the present study, 
so we can rule out a possible interaction of AChE and 
BChE with blood products as well. While in the CESARO 
study, a wide spectrum of operative disciplines has been 
analysed, and the perioperative enzyme activities showed 
small effect sizes, we can show large effect sizes for BChE 
in this secondary analysis of a homogeneous patient 
group with standardised operative procedure.
BChE activity could be regarded as an inflammatory 
parameter in this context. In the literature, lower levels of 
BChE activity have already been described during inflam-
matory processes, stress and malnutrition.9 11 22 There-
fore, lower levels of BChE activity in complication group 
might reflect perioperative inflammation, which is known 
to promote complications like delirium or infections.20 23 
Conventional markers like CRP and leucocytes did not 
differ in both groups.
Delirium is a complex symptom that is very common 
in operative and nonoperative disciplines in the course 
of hospital stay. The incidence is especially high among 
patients undergoing heart surgery.24 The incidence in 
this patients’ population has been described to be from 
30 up to 80%.25 The incidence of delirium after TAVI is 
reported as 29% in the literature.6 Delirium occurred 
significantly more frequently following TA procedures.26 
In the present study, 26.7% of the patients were diagnosed 
with delirium overall. There was no difference depending 
on TA or TF approach. Perioperative measurement of 
AChE and BChE did not discern between patients with 
and without delirium, which is in accordance with the 
findings by John et al17.
The present study highlights the validity of BChE 
measurements for early detection of high- risk patients 
after TAVI. Surprisingly, the BChE assessment proved 
more effective than the EuroSCORE in discriminating 
between the patient groups making it a valuable biomarker 
for the early detection of high- risk patients. EuroSCORE 
is a well- established clinical assay for the patient mortality 
analysis27 and requires documenting multiple and diverse 
data sets. The data sets are in most cases readily available; 
however, in some cases, a particular set of data might not 
be accessible, delaying or making the scoring impossible. 
By using a POCT system for a single BChE measurement, 
the results of an equally efficient outcome assessment tool 
are readily available at the bedside and may complete 
conventional assessments. Further studies with a greater 
patient population are needed to investigate the clinical 
implications.
Prompt assessment of the systemic immune response 
with an immediate, rapid and affordable bedside 
measurement of the BChE activity might improve risk 
evaluation and help optimise postoperative management 
and therapy of patients after TAVI. Predicting the length 
of the hospital stay might play an important role in staff 
and resource management for these patients.
Limitations
Limitations of the present study might be the short dura-
tion of 3 days’ measurement. Blood was taken from each 
patient; in case the analysis could not be performed imme-
diately (during anaesthesia induction), the sample was 
cooled down in a refrigerator. Maybe values of AChE and 
BChE changed in combination with lower temperature. 
Furthermore, it was only one measurement performed 
with each sample, so no control values could be achieved.
The study protocol required daily cholinesterase activity 
measurements in the postoperative period, without spec-
ifying time or requesting multiple daily measurements. 
Therefore, circadian fluctuations in enzyme activities 
could not be considered.
The biggest limitation of the present study is the low 
number of included patients and the related statistical 
power. Further studies with larger patient groups and 
with focus on the underlying mechanisms of the different 
complications would be needed to validate our findings 
and the clinical implications. A larger, possibly multi-
centre study would be needed to evaluate more postop-
erative complications and the roles of BChE and AChE in 
particular complications.
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